Key facts
- Healshape’s last known valuation is $34.8M (Mar 2026).
- It has raised $17.7M; the latest was Later Stage VC ($10.6M) in Mar 2026.
- Notable investors include Bpifrance, La French Tech, GO Capital, Angels Santé, Crédit Agricole Création — 11 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 11 names
- ·Watchlist + deal alerts for Healshape
- ·The full record, as it builds
Funding rounds
No funding rounds for Healshape are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Healshape
Developer of regenerative tissue engineering technology designed for soft tissue reconstruction. The company's platform combines biochemistry, biomaterials science, and 3D bioprinting to produce personalized, bioresorbable bioprostheses from natural materials that integrate with the body, promote in situ tissue regeneration, gradually resorb as native tissue forms, and avoid permanent synthetic implants for patients undergoing reconstructive procedures, enabling patients and surgeons to support autologous tissue regeneration for breast reconstruction and other medical or aesthetic soft tissue repair applications.
- Sector
- Healthcare
- HQ
- Lyon, France
- Founded
- 2020
- Employees
- 26
- Website
- healshape.com/
- Ownership
- Privately Held (backing)
Healshape doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Healshape shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Healshape in its N-PORT filings yet. We sweep new filings monthly.